Zobrazeno 1 - 10
of 154
pro vyhledávání: '"VX-680"'
Autor:
Xumei Liu, Qiong Shi, Namrta Choudhry, Ting Zhang, Hong Liu, Shenqiu Zhang, Jing Zhang, Dun Yang
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 20; Pages: 12104
Small molecule inhibitors of aurora kinases are currently being investigated in oncology clinical trials. The long-term effects of these inhibitors on proliferating euploid cells have not been adequately studied. We examined the effect of the reversi
Autor:
Rong Zhao, Xiaoxia Wang, Yuan Wei, Xuewei Wang, Xiuli Wang, Jiefeng He, Junting Kou, Xiaozhong Li
Publikováno v:
Anti-Cancer Drugs. 32:969-977
Esophageal squamous cell carcinoma (ESCC) is malignant cancer with a high mortality rate. Cisplatin is one of the most potent chemotherapy agents used in the treatment of ESCC. However, chemoresistance and severe adverse effects of cisplatin become m
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Cellular Immunology. 2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
John D. Minna, Michael G. Roth, Vural Tagal, Tae Hyun Hwang, David A. Wheeler, Bruce A. Posner, Adi F. Gazdar, Rolf A. Brekken, Wei Zhang, Luc Girard, Shuguang Wei, Michael A. White, Michael Peyton
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature Communications
Mutations in the SMARCA4/BRG1 gene resulting in complete loss of its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells. Currently, no single therapeutic agent has been identified as synthetically lethal with SMARCA4/BRG1 los
Publikováno v:
Experimental Cell Research. 394:112112
Inhibition of Aurora-B kinase is a synthetic lethal therapy for tumors that overexpress the MYC oncoprotein. It is currently unclear whether co-occurring oncogenic alterations might influence this synthetic lethality by conferring more or less potenc
Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis
Autor:
Shishi Niu, Chengyuan Yang, Xiaozhong Li, Zhen Zhang, Xuejiao Sun, Zichan Guo, Anyan Wang, Yuepeng Hao, Xiaoxia Wang
Publikováno v:
Molecular medicine reports. 19(5)
Angiogenesis serves a key role in tumor growth and metastasis. VX‑680, a potent inhibitor targeting the Aurora kinase family, is widely used in the inhibition of tumor progression. However, the effect of VX‑680 on angiogenesis remains unknown. Th
Autor:
Sam Hofmans, Vera Goossens, Koen Augustyns, Nozomi Takahashi, Lars Devisscher, Polien Claeys, Sofie Martens, Peter Vandenabeele, Marnik Vuylsteke
Publikováno v:
Cell Death & Disease
CELL DEATH & DISEASE
Cell Death and Disease
Cell Death and Disease, Vol 9, Iss 2, Pp 1-13 (2018)
CELL DEATH & DISEASE
Cell Death and Disease
Cell Death and Disease, Vol 9, Iss 2, Pp 1-13 (2018)
The Aurora kinase family (Aurora A, B and C) are crucial regulators of several mitotic events, including cytokinesis. Increased expression of these kinases is associated with tumorigenesis and several compounds targeting Aurora kinase are under evalu